Marie – Interview 18
Marie was diagnosed with chronic lymphocytic leukaemia after pains in her bones and groin. After two years of watch and wait she had several courses of oral chemotherapy with remissions in between. She is currently well but expects further treatment. Marie was also interviewed for the clinical trials section of this site.
On her return from living in Africa in 1989 Marie developed pains which her GP attributed to the change in climate and possible rheumatism. A year later a pain in her groin prompted the GP to do a blood test. Marie was referred to a consultant who told her it was chronic lymphocytic leukaemia. She was shocked and assumed it meant she would die but was told that her disease had been caught early so would be monitored with regular blood tests and she should get on with her life.
She spent two years watching and waiting’ during which time her symptoms became more troublesome and she began to feel tired. She was then given two courses of chemotherapy tablets called chlorambucil, which got rid of her symptoms without producing any side effects. After another two years she had another six months of chlorambucil. She was also given steroids which gave her lots of energy but caused weight gain. She was diagnosed with diabetes but cured that through dieting. More chlorambucil followed.
Three years ago her body failed to respond to the chlorambucil in the usually way so she was given FluCy (a combination of fludarabine and cyclophosphamide), also in tablet form. The first course made her feel better but a further two courses had no effect so the planned fourth course was held back for another time. She was well again for fourteen months but then began to feel tired, had pains under her arms and a lump formed in her neck and she had no immunity to infections.
Marie’s consultant invited her to take part in a drug company-run clinical trial of a new monoclonal antibody called HuMax-CD20. She tentatively agreed to take part but after reading all the details decided against it. She was therefore given her fourth course of FluCy along with blood transfusions and antibodies to boost her immune system and now feels well again. When her symptoms return next time she is expecting to be given a different chemotherapy administered intravenously. In the mean time she continues to get on with her life.
Marie was also interviewed for the clinical trials section of this site (see Interview CLT25).